Focused Ultrasound Clinical Trials Advanced Cancer Care
Researchers are testing focused ultrasound and histotripsy to target difficult pancreatic and brain tumors.
Updated on Sept. 19, 2026 in Cancer
Live Poll
Should experimental medical technologies be available to patients before large-scale clinical trials are completed?
In April 2026, researchers expanded the reach of focused ultrasound technology by initiating clinical trials for pancreatic and brain cancer treatment. This method utilizes precise acoustic energy beams to destroy tumor tissue without the need for traditional surgery.
Why it matters
These trials aim to provide life-saving interventions for tumors that are notoriously difficult to manage with conventional surgical techniques. The technology offers a non-invasive alternative that could significantly improve patient outcomes.
There are currently 2,000 focused ultrasound systems in use worldwide, with projections estimating an increase to 10,000 units within five years. To date, over 1 million patients globally have received treatment using these acoustic platforms.
The players
Focused Ultrasound Foundation
This organization leads global efforts to accelerate the development and adoption of non-invasive ultrasound treatments.
Gleneagles Hospital
Located in Hong Kong, this medical facility serves as a primary site for advanced clinical research and specialized oncological procedures.
The details
The technology directs multiple beams of acoustic energy at a precise target inside the body to destroy tissue or modulate brain circuits, while histotripsy specifically uses the process to destroy tumor tissue. Gleneagles Hospital in Hong Kong recently performed two such procedures as part of its clinical investigation.
Timeline
The Focused Ultrasound Foundation was founded in 2006.
Nearly 75,000 patients received focused ultrasound treatment in 2025.
Gleneagles Hospital performed first pancreatic cancer clinical trials in April 2026.
Expected results from pancreatic and brain cancer trials are due within 3 years.
The number of ultrasound systems is projected to reach 10,000 within 5 years.
The Big Picture
This story follows a pattern set by the Focused Ultrasound Foundation's clinical research framework to diversify therapeutic applications. The integration of histotripsy marks a significant expansion from standard ultrasound imaging into active tissue destruction.
These non-invasive procedures offer patients a surgical alternative that may reduce recovery times and complications associated with traditional operations. While currently limited to clinical trials, the technology represents a potential future shift in how doctors approach aggressive tumor removal.
The takeaway
Focused ultrasound is rapidly evolving from an imaging tool into a robust therapeutic platform for oncology. Patients should continue to monitor clinical trial registry updates for new opportunities to access these experimental procedures as they scale.
Further reading
For more information on the latest advancements in oncological research, visit the Cancer section.
Live Poll
Should experimental medical technologies be available to patients before large-scale clinical trials are completed?
